ENTRY       D10820                      Drug
NAME        Olipudase alfa (USAN/INN);
            Olipudase alfa (genetical recombination) (JAN);
            Olipudase alfa-rpcp;
            Xenpozyme (TN)
PRODUCT     XENPOZYME (Genzyme Corporation)
FORMULA     C2900H4373N783O791S24
EXACT_MASS  63590.933
MOL_WEIGHT  63631.0831
SEQUENCE    HPLSPQGHPA RLHRIVPRLR DVFGWGNLTC PICKGLFTAI NLGLKKEPNV ARVGSVAIKL
            CNLLKIAPPA VCQSIVHLFE DDMVEVWRRS VLSPSEACGL LLGSTCGHWD IFSSWNISLP
            TVPKPPPKPP SPPAPGAPVS RILFLTDLHW DHDYLEGTDP DCADPLCCRR GSGLPPASRP
            GAGYWGEYSK CDLPLRTLES LLSGLGPAGP FDMVYWTGDI PAHDVWHQTR QDQLRALTTV
            TALVRKFLGP VPVYPAVGNH ESTPVNSFPP PFIEGNHSSR WLYEAMAKAW EPWLPAEALR
            TLRIGGFYAL SPYPGLRLIS LNMNFCSREN FWLLINSTDP AGQLQWLVGE LQAAEDRGDK
            VHIIGHIPPG HCLKSWSWNY YRIVARYENT LAAQFFGHTH VDEFEVFYDE ETLSRPLAVA
            FLAPSATTYI GLNPGYRVYQ IDGNYSGSSH VVLDHETYIL NLTQANIPGA IPHWQLLYRA
            RETYGLPNTL PTAWHNLVYR MRGDMQLFQT FWFLYHKGHP PSEPCGTPCR LATLCAQLSA
            RADSPALCRH LMPDGSLPEA QSLWPRPLFC
            (Disulfide bridge: 43-119, 46-111, 74-85, 175-180, 181-204, 339-385, 538-542, 548-561)
  TYPE      Peptide
REMARK      Therapeutic category: 3959
            ATC code: A16AB25
            Product: D10820<JP/US>
EFFICACY    Lysosomal storage disease treatment, Enzyme replacement (acid sphingomyelinase)
  DISEASE   Acid sphingomyelinase deficiency [DS:H00137]
  TYPE      Enzyme replacement therapy product
COMMENT     Treatment of Niemann-Pick disease type A/B
TARGET      SMPD1* [HSA_VAR:6609v1] [HSA:6609] [KO:K12350]
  PATHWAY   hsa00600(6609)  Sphingolipid metabolism
            hsa04071(6609)  Sphingolipid signaling pathway
            hsa04142(6609)  Lysosome
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
               A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
                A16AB Enzymes
                 A16AB25 Olipudase alfa
                  D10820  Olipudase alfa (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
              Olipudase Alfa
               D10820  Olipudase alfa (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               395  Enzyme preparations
                3959  Others
                 D10820  Olipudase alfa (USAN/INN); Olipudase alfa (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Phosphodiesterases
                SMPD1* [HSA_VAR:6609v1]
                 D10820  Olipudase alfa (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10820
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10820
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10820
            Pharmacogenomic biomarkers [br08341.html]
             Germline mutations in genetic disorder treatments
              D10820
DBLINKS     CAS: 927883-84-9
            PubChem: 319902620
///
